A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

March 4, 2014 updated by: SANUWAVE, Inc.

A Double-Blind, Multi-center, Randomized, Sham-Controlled, Parallel Group Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers

The Sponsor of this study, SANUWAVE, Inc., has developed an investigational device known as the dermaPACE® (Pulsed Acoustic Cellular Expression) device for the possible treatment of diabetic foot ulcers. This device generates acoustic (sound) pressure waves designed to act on the cells in your body to generate proteins that may lead to wound closure. The dermaPACE® device has not been approved for the treatment of diabetic foot ulcers; therefore its use in this study is investigational.

The purpose of the study is to evaluate the ability of the dermaPACE® device to help diabetic foot ulcers heal more quickly. The active study device, the dermaPACE®, will be compared to an inactive look-alike device (called a "Sham") in this study. The sham device will not provide any treatment to your diabetic foot ulcer.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Hamilton, Ontario, Canada, L8R 2R3
        • Recruiting
        • The Mayer Institute
        • Contact:
        • Principal Investigator:
          • Perry Mayer, MD
  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85015
        • Recruiting
        • Associated Foot and Ankle Specialists
        • Contact:
        • Principal Investigator:
          • Arthur Tallis, DPM
      • Tucson, Arizona, United States, 85723
        • Recruiting
        • Southern Arizona VA Healthcare System
        • Contact:
        • Principal Investigator:
          • Jodi L Walters, DPM
    • California
      • Long Beach, California, United States, 90822
        • Recruiting
        • Long Beach VA Healthcare System
        • Contact:
        • Principal Investigator:
          • Ian Gordon, MD, PhD
      • Los Angeles, California, United States, 90010
        • Recruiting
        • Foot and Ankle Clinic
        • Contact:
      • Oakland, California, United States, 94602
        • Recruiting
        • Alameda County Medical Center - Highlands Campus
        • Contact:
        • Principal Investigator:
          • Timothy Dutra, DPM
      • San Bernardino, California, United States, 92404
        • Recruiting
        • Lucius J. Hill DPM
        • Contact:
        • Principal Investigator:
          • Lucius J Hill, DPM
    • Florida
      • Hialeah, Florida, United States, 33013
        • Recruiting
        • Paul and Margaret Brand Research Center at Barry University
        • Contact:
        • Principal Investigator:
          • Robert F Snyder, DPM
      • Hialeah, Florida, United States, 33016
        • Recruiting
        • The Research Center
        • Contact:
        • Principal Investigator:
          • Gilberto J Acosta, DPM
      • Jacksonville, Florida, United States, 32207
        • Recruiting
        • River City Clinical Research
        • Contact:
        • Principal Investigator:
          • William Namen II, DPM
      • Miami, Florida, United States, 33126
        • Recruiting
        • St. Paul Medical Research
        • Contact:
        • Principal Investigator:
          • John G Padron, MD
      • Miami, Florida, United States, 33137
        • Recruiting
        • Advanced Pharma CR
        • Contact:
        • Principal Investigator:
          • Gilbert Weiner, MD
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern University, Div of Plastic and Reconstructive Surgery
        • Contact:
    • Michigan
      • Southfield, Michigan, United States, 48076
        • Recruiting
        • Foot Healthcare Associates
        • Contact:
        • Principal Investigator:
          • Neal Mozen, DPM
    • North Carolina
      • Asheville, North Carolina, United States, 28806
        • Recruiting
        • Moore Foot and Ankle Specialists
        • Contact:
        • Principal Investigator:
          • J. Christopher Moore, DPM
    • Pennsylvania
      • Kittaning, Pennsylvania, United States, 16201
        • Recruiting
        • Wound Center - ACMH
        • Contact:
    • Texas
      • Dallas, Texas, United States, 75390
      • Dallas, Texas, United States, 75224
        • Recruiting
        • Podiatric Medical Partners of Texas
        • Contact:
        • Principal Investigator:
          • Richard C Galperin, DPM
    • Virginia
      • Roanoke, Virginia, United States, 24016
        • Recruiting
        • Foot and Ankle Associates of SW Virginia
        • Contact:
        • Principal Investigator:
          • Charles M. Zelen, DPM

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Is >=22 years of age at Visit 1;

  2. If female of child-bearing potential, both of the following must be met at Visit 1:

    • Practices one of the following methods of contraception and continues through the duration of the study: hormonal contraceptives, IUD, spermicide and barrier or implantable device, and
    • Has a negative urine qualitative beta-HCG pregnancy test;

  3. If female and post-menopausal one of the following must be met at Visit 1:

    • Has had a complete hysterectomy, bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy, or
    • Is postmenopausal for at least one year;
  4. Has at least one DFU that is located in the ankle area or below that has persisted a minimum of 30 days prior to Visit 1.
  5. Has Type I or Type II Diabetes Mellitus with a HbA1c <= 11% at Visit 1;
  6. Is capable of wound care at home;
  7. Has a target ulcer >= 1.0 cm2 and <= 16 cm2 at Visits 1 and 2;
  8. Has a target ulcer that is Grade 1 or 2, Stage A according to the University of Texas Diabetic Wound Classification system, at Visits 1 and 2
  9. In the leg with the target ulcer has an ABI >= 0.70 and <= 1.20 OR if the ABI is >1.20 has a toe pressure >50 mmHg OR tcpO2 > 40 mmHg at Visit 1;
  10. Subject agrees, or if applicable, the subject's legal representative agrees that the subject can participate in the study

Exclusion Criteria:

  1. Is currently pregnant or plans to become pregnant during the study;
  2. Is nursing or actively lactating;
  3. Is morbidly obese (Body Mass Index >= 40) at Visit 1;
  4. Has clinically significant renal disease defined as having an estimated creatinine clearance of <=40mL/min at Visit 1;
  5. Has osteomyelitis in the foot or ankle on which the target ulcer is located at Visit 1 or 2;
  6. Has evidence of a prior ulcer in the same area as the target ulcer;
  7. Has a target ulcer that has decreased in volume by 50% or more at Visit 2 as compared to the volume at Visit 1;
  8. Has multiple foot ulcers that are connected by fistulas or has an ulcer(s) that are within 5 cm of the target ulcer at Visit 1 or 2;
  9. Has a target ulcer that tunnels into wound tracks which cannot be fully visualized from the wound surface at Visit 1 or 2;
  10. Has active cellulitis either at the site of, or in the surrounding area of, the target ulcer at Visit 1 or 2;
  11. Has a target ulcer that has visually purulent exudates or that has malodorous exudates on examination at Visit 1 or 2;
  12. Has PVD, per Doppler Ultrasound, requiring vascular surgery intervention at Visit 1 or 2;
  13. Requires use of off-loading Diabetic Walker device for the foot intended for study application for a reason other than for a target ulcer on the plantar surface of the foot at Visit 1 or 2;
  14. Has had a lower extremity revascularization procedure within eight weeks of Visit 1;
  15. Has active Charcot foot at Visit 1 or 2;
  16. Has had a surgical procedure to correct biomechanical abnormities within eight weeks of Visit 1;
  17. Has had a deep vein thrombosis within six months of Visit 1;
  18. Has clinical evidence of lymphedema at Visit 1;
  19. Has had chemotherapy within 60 days of Visit 1;
  20. Has a life expectancy <=2 years;
  21. Has previously participated in a dermaPACE diabetic foot ulcer study;
  22. Has had treatment of the target ulcer with growth factors, prostaglandin therapy, negative pressure or vasodilator therapy within two weeks of Visit 1;
  23. Is receiving >=10 mg/day of steroid therapy;
  24. Has sickle cell anemia;
  25. Has a known immunodeficiency disorder to include, but not be limited to: AIDS, HIV, etc.
  26. Has received radiation treatment within 120 days of Visit 1;
  27. Has received treatment with immunosuppressants within sixty days of Visit 1;
  28. Has received treatment with biologically active cellular products on the target ulcer, e.g. Apligraf®, Dermagraft®, etc. within sixty days of Visit 1;
  29. Has received treatment with acellular (collagen-based) products on the target ulcer, e.g. Alloderm®, Integra®, etc. within 30 days of Visit 1;
  30. Has a current history of substance abuse (current is defined as within 120 days of Visit 1);
  31. Has a history of major systemic infections requiring hospitalization within three months of Visit 1 ;
  32. Has a current malignancy or a history of malignancy within five years, of Visit 1 except for basal cell carcinoma that has been treated with local excision and is no longer present;
  33. Has a physical or mental disability or geographical concerns that would inhibit compliance with required study visits;
  34. Is planning to undergo an exclusionary treatment or procedure during the study; or
  35. Has participated in another investigation within 30 days of Visit 1

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Active device plus standard of care
Device: Electrohydraulic-generated shock wave
Other Names:
  • dermaPACE
SHAM_COMPARATOR: Sham device plus standard of care
dermaPACE device that uses a dummy applicator that does not emit shock waves
Device: Sham device plus standard of care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complete closure
Time Frame: 12 weeks
Complete closure will be assessed by visual inspection by the principal or sub-investigator according to the following complete closure definition: 100% skin re-epithelializion without drainage or dressing requirements confirmed at two consecutive study visits. A re-epithelialized target ulcer is defined as the tissue surface having at least a thin layer of epithelium covering the prior, previously denuded, target ulcer area.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Volumetric reduction
Time Frame: 12 weeks
Digital planimetry will be used to assess volumetric reduction between follow-up visits.
12 weeks
Area reduction
Time Frame: 12 weeks
Digital planimetry will be used to assess area reduction between follow-up visits.
12 weeks
Rate of recurrence
Time Frame: 24 weeks
24 weeks
Rate of amputation and other adverse events
Time Frame: 24 weeks
24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SANUWAVE, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2013

Primary Completion (ANTICIPATED)

April 1, 2014

Study Registration Dates

First Submitted

April 1, 2013

First Submitted That Met QC Criteria

April 1, 2013

First Posted (ESTIMATE)

April 4, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

March 6, 2014

Last Update Submitted That Met QC Criteria

March 4, 2014

Last Verified

March 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SAN12-DERM02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot Ulcers

Clinical Trials on Electrohydraulic-generated shock wave

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe